×
Kamada Receivables 2012-2024 | KMDA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Kamada receivables from 2012 to 2024. Receivables can be defined as the total amount of collectibles for a company
View More
Kamada Receivables 2012-2024 | KMDA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Kamada receivables from 2012 to 2024. Receivables can be defined as the total amount of collectibles for a company
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$172.8B
Vertex Pharmaceuticals (VRTX)
$125.8B
Regeneron Pharmaceuticals (REGN)
$111.1B
Bristol Myers Squibb (BMY)
$108.2B
Gilead Sciences (GILD)
$108B
CSL (CSLLY)
$97B
GSK (GSK)
$81.3B
Alnylam Pharmaceuticals (ALNY)
$38.6B
Argenex SE (ARGX)
$32.3B
BioNTech SE (BNTX)
$28B
Biogen (BIIB)
$27.5B
Illumina (ILMN)
$22.9B
Moderna (MRNA)
$22.1B
BeiGene (BGNE)
$21.6B
Genmab (GMAB)
$15B
BioMarin Pharmaceutical (BMRN)
$13.3B
Insmed (INSM)
$13.2B
Vaxcyte (PCVX)
$13.2B
Exact Sciences (EXAS)
$13B
Incyte (INCY)
$12.7B
Sarepta Therapeutics (SRPT)
$12B
Bio-Techne Corp (TECH)
$11.4B
QIAGEN (QGEN)
$9.9B
Bio-Rad Laboratories (BIO.B)
$9.3B
Roivant Sciences (ROIV)
$8.9B
Revolution Medicines (RVMD)
$8.4B
Exelixis (EXEL)
$8.4B
Intra-Cellular Therapies (ITCI)
$8B
Legend Biotech (LEGN)
$8B
Ascendis Pharma (ASND)
$7.9B